CN1836041A - 浏览突变 - Google Patents

浏览突变 Download PDF

Info

Publication number
CN1836041A
CN1836041A CNA2004800229706A CN200480022970A CN1836041A CN 1836041 A CN1836041 A CN 1836041A CN A2004800229706 A CNA2004800229706 A CN A2004800229706A CN 200480022970 A CN200480022970 A CN 200480022970A CN 1836041 A CN1836041 A CN 1836041A
Authority
CN
China
Prior art keywords
library
polypeptide
polynucleotide
amino acid
designation area
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800229706A
Other languages
English (en)
Chinese (zh)
Inventor
R·克里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R Crea & Co
Original Assignee
R Crea & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Crea & Co filed Critical R Crea & Co
Publication of CN1836041A publication Critical patent/CN1836041A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CNA2004800229706A 2003-06-27 2004-06-25 浏览突变 Pending CN1836041A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48328203P 2003-06-27 2003-06-27
US60/483,282 2003-06-27

Publications (1)

Publication Number Publication Date
CN1836041A true CN1836041A (zh) 2006-09-20

Family

ID=33563915

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800229706A Pending CN1836041A (zh) 2003-06-27 2004-06-25 浏览突变

Country Status (14)

Country Link
US (1) US20050136428A1 (enExample)
EP (1) EP1660655B1 (enExample)
JP (2) JP4791960B2 (enExample)
KR (1) KR20060034650A (enExample)
CN (1) CN1836041A (enExample)
AU (1) AU2004254352A1 (enExample)
BR (1) BRPI0412007A (enExample)
CA (1) CA2542192C (enExample)
ES (1) ES2609102T3 (enExample)
IL (1) IL172736A0 (enExample)
NO (1) NO20060108L (enExample)
RU (1) RU2005140664A (enExample)
WO (1) WO2005003345A2 (enExample)
ZA (1) ZA200510460B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104805507A (zh) * 2014-01-29 2015-07-29 杭州精微致广生物技术有限公司 噬菌体展示文库及其应用和制备方法
CN104955961A (zh) * 2012-12-11 2015-09-30 塞勒密斯株式会社 利用密码子随机化和诱变来合成基因文库的方法
TWI572618B (zh) * 2013-04-18 2017-03-01 財團法人生物技術開發中心 對抗介白素－２０之人類化抗體及發炎性疾病之治療
CN101778940B (zh) * 2007-06-06 2017-04-05 丹尼斯科美国公司 改进多种蛋白质性质的方法
CN106986935A (zh) * 2009-08-21 2017-07-28 英国龙沙生物医药股份有限公司 具有改进的可产生性的变体免疫球蛋白
CN117672369A (zh) * 2022-09-01 2024-03-08 珠海碳云智能科技有限公司 一种基于多肽芯片的抗体表位的高通量鉴定方法

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329725B1 (en) * 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
EP1781680B8 (en) 2004-07-06 2016-05-18 Bioren, LLC Universal antibody libraries
WO2006014477A1 (en) * 2004-07-06 2006-02-09 Bioren, Inc. HIGH AFFINITY ANTI-TNF-α ANTIBODIES AND METHOD
ATE528396T1 (de) 2004-07-06 2011-10-15 Bioren Inc Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften
WO2006094234A1 (en) * 2005-03-03 2006-09-08 Xencor, Inc. Methods for the design of libraries of protein variants
US20080207467A1 (en) * 2005-03-03 2008-08-28 Xencor, Inc. Methods for the design of libraries of protein variants
CA2605697A1 (en) * 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
WO2007019620A1 (en) * 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
US8716195B2 (en) * 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
US20110129414A1 (en) * 2005-11-15 2011-06-02 Balyasnikova Irina V Single Chain Fragment of Monoclonal Antibody 9B9 and Uses Thereof
US20090286962A1 (en) 2005-12-20 2009-11-19 Woolven Benjamin P Chimeric antibodies with part new world primate binding regions
NZ569988A (en) 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
US20070224627A1 (en) * 2006-03-23 2007-09-27 Lawrence Horowitz Facilitation of translocation of molecules through the gastrointestinal tract
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
WO2007136840A2 (en) * 2006-05-20 2007-11-29 Codon Devices, Inc. Nucleic acid library design and assembly
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US8131480B2 (en) 2006-10-02 2012-03-06 Sea Lane Biotechnologies Llc Construction of diverse synthetic peptide and polypeptide libraries
WO2008045380A2 (en) * 2006-10-04 2008-04-17 Codon Devices, Inc. Nucleic acid libraries and their design and assembly
WO2009009045A2 (en) * 2007-07-10 2009-01-15 The Scripps Research Institute Escape libraries of target polypeptides
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
CA2719201A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc. Neutralizing molecules to viral antigens
EP2131244A3 (en) * 2008-06-02 2012-04-11 ASML Netherlands BV Lithographic apparatus and method for measuring a pattern property
MX2011010681A (es) 2009-04-10 2012-01-20 Ablynx Nv Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
CN102459332B (zh) 2009-06-05 2015-08-19 埃博灵克斯股份有限公司 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
SG10201700096VA (en) * 2009-07-17 2017-02-27 Bioatla Llc Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
AU2011283646B2 (en) 2010-07-30 2015-07-09 Novartis Ag Fibronectin cradle molecules and libraries thereof
JP5920835B2 (ja) 2010-12-01 2016-05-18 田辺三菱製薬株式会社 無細胞翻訳系でＦａｂを提示しうるポリヌクレオチド構築物ならびにそれを用いたＦａｂの製造方法およびスクリーニング方法
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
JP6415987B2 (ja) 2012-03-02 2018-10-31 アブリンクス エン．ヴェー． シュードモナス・エルギノーサのＰｃｒＶに結合する単一可変ドメイン抗体
USRE49477E1 (en) * 2012-04-20 2023-03-28 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
EP3929288A1 (en) 2012-05-25 2021-12-29 Chr. Hansen A/S Variants of chymosin with improved milk-clotting properties
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
CA2924520C (en) * 2013-11-01 2023-09-26 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
RU2739004C1 (ru) 2014-02-26 2020-12-21 Кхр. Хансен А/С Варианты химозина с улучшенными молокосвертывающими свойствами
CA2963712A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
EP3310914B1 (en) 2015-06-22 2022-04-06 Chr. Hansen A/S Variants of chymosin with improved properties
AU2016315269B2 (en) 2015-08-31 2021-09-23 Chr. Hansen A/S Variants of chymosin with improved properties
JP6803619B2 (ja) * 2016-01-08 2020-12-23 桃太郎源株式会社 ＲＥＩＣ／Ｄｋｋ−３遺伝子およびチェックポイント阻害剤を用いた併用療法
AR108526A1 (es) 2016-05-19 2018-08-29 Chr Hansen As Variantes de quimosina con propiedades mejoradas de coagulación de la leche
AR108527A1 (es) 2016-05-19 2018-08-29 Chr Hansen As Variantes de quimosina con propiedades mejoradas de coagulación de leche
CN117298260A (zh) * 2016-09-02 2023-12-29 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
WO2019118918A1 (en) 2017-12-15 2019-06-20 Aleta Biotherapeutics Inc. Cd19 variants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079802C (en) * 1990-04-05 2001-09-18 Roberto Crea Walk-through mutagenesis
WO1995023813A1 (en) * 1994-03-04 1995-09-08 Merck & Co., Inc. In vitro antibody affinity maturation using alanine scanning mutagenesis
JP2003516755A (ja) * 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101778940B (zh) * 2007-06-06 2017-04-05 丹尼斯科美国公司 改进多种蛋白质性质的方法
CN106986935A (zh) * 2009-08-21 2017-07-28 英国龙沙生物医药股份有限公司 具有改进的可产生性的变体免疫球蛋白
CN104955961A (zh) * 2012-12-11 2015-09-30 塞勒密斯株式会社 利用密码子随机化和诱变来合成基因文库的方法
CN104955961B (zh) * 2012-12-11 2017-03-08 塞勒密斯株式会社 利用密码子随机化和诱变来合成基因文库的方法
US10036007B2 (en) 2012-12-11 2018-07-31 Celemics, Inc. Method of synthesis of gene library using codon randomization and mutagenesis
TWI572618B (zh) * 2013-04-18 2017-03-01 財團法人生物技術開發中心 對抗介白素－２０之人類化抗體及發炎性疾病之治療
CN104805507A (zh) * 2014-01-29 2015-07-29 杭州精微致广生物技术有限公司 噬菌体展示文库及其应用和制备方法
CN104805507B (zh) * 2014-01-29 2019-01-22 杭州康万达医药科技有限公司 噬菌体展示文库及其应用和制备方法
CN117672369A (zh) * 2022-09-01 2024-03-08 珠海碳云智能科技有限公司 一种基于多肽芯片的抗体表位的高通量鉴定方法

Also Published As

Publication number Publication date
EP1660655A2 (en) 2006-05-31
WO2005003345A3 (en) 2005-03-24
BRPI0412007A (pt) 2006-08-15
JP2007524390A (ja) 2007-08-30
JP5358604B2 (ja) 2013-12-04
JP4791960B2 (ja) 2011-10-12
US20050136428A1 (en) 2005-06-23
KR20060034650A (ko) 2006-04-24
EP1660655B1 (en) 2016-11-02
RU2005140664A (ru) 2007-08-27
JP2011182794A (ja) 2011-09-22
AU2004254352A1 (en) 2005-01-13
CA2542192A1 (en) 2005-01-13
WO2005003345A2 (en) 2005-01-13
ES2609102T3 (es) 2017-04-18
IL172736A0 (en) 2006-04-10
CA2542192C (en) 2013-05-28
NO20060108L (no) 2006-03-24
ZA200510460B (en) 2006-11-29

Similar Documents

Publication Publication Date Title
CN1956996A (zh) 基于泛素蛋白的人工结合蛋白的生产
CN101080496A (zh) 抗体工程改造方法
CN1305905C (zh) 人源化抗体及其制备方法
CN1105728C (zh) 用于治疗il4介导疾病的重组il4抗体
CN1839144A (zh) 兔单克隆抗体的人源化方法
CN1662556A (zh) 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN1246335C (zh) 用于治疗il－18介导疾病的重组il－18拮抗物
CN1173878A (zh) 双功能或双价抗体片段类似物
CN1688338A (zh) 对免疫系统分子进行人源化的方法
JP4791960B2 (ja) ルックスルー突然変異誘発
CN1946422A (zh) 针对血管内皮生长因子的人源化抗体
EP3434769B1 (en) Universal fibronectin type iii bottom-side binding domain libraries
CN1809592A (zh) 识别n－乙醇酰gm3神经节苷脂的重组抗体和片段以及其在肿瘤诊断和治疗上的应用
CN1829806A (zh) 产生高亲和力抗体的方法
CN1145641A (zh) 通过随机片段化和重装配进行的dna诱变
US20070184518A1 (en) Stabilized proteins
CN1906212A (zh) 抗体人源化的方法以及由此获得的人源化抗体
CN1596313A (zh) 人源化的胶原抗体及相关方法
CN1076966A (zh) 抗人白细胞介素-4的人性化单克隆抗体的克隆和表达
CN1077991A (zh) 具有人属性的抗人白细胞介素-5的单克隆抗体的设计，克隆和表达
CN1606569A (zh) 具有mn结合和细胞粘附中和活性的人类抗体
CN101058609A (zh) 人源抗体及其表达
CN1756767A (zh) 在丝状真菌中表达人重链抗体
CN1423561A (zh) 丙型肝炎治疗药
CN1289668C (zh) 一种用于抗体改形的体外分子定向进化方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1091232

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1091232

Country of ref document: HK